

November 30, 2010

Robyn Zolman
Direct: 303.298.5740
Fax: 303.313.2830
RZolman@gibsondunn.com

Client: C 12412-00001

VIA EDGAR

Ms. Rose Zukin
Division of Corporation Finance
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549

Re: BioCryst Pharmaceuticals, Inc.
Form 10-K for the year ended December 31, 2009
Filed March 9, 2010
Definitive Proxy Statement on Schedule 14A
Filed April 6, 2010
File No. 000-23186

Dear Ms. Zukin:

On behalf of BioCryst Pharmaceuticals, Inc. (the "Company") this letter confirms that as discussed with you today, the Company will respond to the Staff's November 16, 2010 letter to the Company on or before December 15, 2010.

Sincerely,

/s/ Robyn Zolman

Robyn Zolman

REZ/rez

cc: Alane Barnes, BioCryst Pharmaceuticals, Inc.
Brian Lane, Gibson, Dunn & Crutcher LLP